Drug firm Lupin today said it has inked a pact with Eli Lilly to promote and distribute the US firm's anti-diabetic drugs, including Huminsulin RTM, in India and Nepal.
"Lupin and Eli Lilly have entered into a strategic collaboration to promote and distribute Lilly's Huminsulin range of products, including Huminsulin RTM, Huminsulin NPHTM, Huminsulin 50/50TM, Huminsulin 30/70TM and Humapen Ergo II," Lupin said in a statement.
Lupin's India formulations business will promote and distribute the range of products in India and Nepal, virtually doubling the number of sales representatives behind the diabetes care product, it added.
According to IMS June 2011 data, the total Indian insulin market is valued at Rs 975 crore and Huminsulin is the second biggest brand portfolio in the same.
"Lupin will market and distribute the entire range of Huminsulin brand. The total sales of the brand is close to Rs 125 crore," the company said.
Shares of Lupin today closed at Rs 454.60 on BSE, up 1.15% from its previous close.